LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial
| Autor: | Trivedi, M.S., Shatsky, R.A., Nanda, R., Rugo, H.S., Omene, C., Kalinsky, K., Roussos Torres, E.T., Thomas, B., Sanford, A., Albain, K.S., Clark, A.S., Falkson, C.I., Isaacs, C., Thomas, A., Tseng, J., Van't Veer, L.J., Hylton, N., Yee, D., Yau, C., Esserman, L. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S1208-S1209 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|